Skip to main content
SpringerLink
Log in

Riferminogene Pecaplasmide

  • Adis R&D Profile
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Vical Incorporated. Vical Receives Milestone From Gencell for Cardiovascular Gene Delivery Applications. http://www.vical.com, 26 Jul 2004.

  2. Vical Incorporated. Vical Licensee Sanofi-aventis Completes Enrollment in Phase 3 Angiogenesis Trial. www.vical.com, 28 Sep 2009.

  3. sanofi-aventis. Sanofi-aventis Announces Second Quarter 2009 Results. www.sanofi-aventis.com, 29 Jul 2009.

  4. Vical Incorporated.Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations. www.vical.com, 20 Sep 2007.

  5. Vical Incorporated. Vical Licensee Sanofi-Aventis Releases Phase 2b Angiogenesis Data and Plans for Phase 3. www.vical.com, 13 Mar 2006.

  6. Vical Incorporated. Vical Reports 2009 Financial Results and Progress in Key Development Programs. www.vical.com, 11 Feb 2010.

  7. Sanofi-aventis. EPS growth in Q2 2010. www.sanofi-aventis.us, 29 Jul 2010.

  8. Vical Incorporated. Vical Reports First Quarter 2006 Financial Results. www.vical.com, 02 May 2006.

  9. Sanofi Aventis. Sanofi-aventis Reports Strong Growth of 25.7% in 2005 Adjusted EPS(1); Nearly 90% of synergies delivered by end 2005; Dividend increased by 26.7%. www.sanofi-aventis.com, 24 Feb 2006.

  10. Eurekalert. Study Analyzes Gene Therapy For Patients At High Risk For Amputation. www.eurekalert.org, 13 Mar 2006.

  11. Henry T, Comerota AJ, Chronos N, et al. Final results of a phase I clinical study to evaluate NV1FGF (human FGF-1 expression plasmid) in patients with critical limb ischemia. Molecular Therapy 5: 289, Part 2, May 2002.

    Google Scholar 

  12. Witzenbichler B, Mahfoudi A, Soubrier F, et al. Intramuscular injection of plasmid DNA encoding fibroblast growth factor-1 induces angiogenesis in a rabbit hindlimb model of peripheral ischaemia. European Heart Journal 20 (Abstract Suppl.): 12, Nov 1999.

    Google Scholar 

  13. Aventis. Aventis R&D Day 2002: Seven Potential Blockbusters by 2006; Pipeline Progress to Help Deliver Sustainable Growth. http://www.aventis.com, 18 Jun 2002.

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Riferminogene Pecaplasmide. Am J Cardiovasc Drugs 10, 343–346 (2010). https://doi.org/10.2165/11533480-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11533480-000000000-00000

Search

Navigation